IDEAYA Biosciences Inc (NASDAQ:IDYA), a United States-based oncology-focused biotechnology company, has dosed its first patient in the phase one combination study of IDE196 and binimetinib, an MEK inhibitor, intended to treat metastatic uveal melanoma (MUM), it was reported on Thursday.

The company is assessing the clinical combination of IDE196 and binimetinib, which is being provided by Pfizer based on a clinical trial collaboration and supply contract.

The company expects interim data from the MEK combination study in late 2021 to early 2022, when the firm will assess a potential registrational path for MUM and a potential collaboration.